← Eichor
Condition: Langerhans Cell Histiocytosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Langerhans Cell Histiocytosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Phase 3 · 11 location(s) · Baylor College of Medicine · NCT02670707Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943224Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Phase 2 · 1 location(s) · Cook Children's Health Care System · NCT06582745Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Phase N/A · 1 location(s) · Eunice Kennedy Shriver National Institute of Child Health an · NCT00344331Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT03329274Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NA · 11 location(s) · West China Second University Hospital · NCT07431060Mirdametinib in Histiocytic Disorders
Phase 2 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06153173Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Phase N/A · 2 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06339177UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
Phase 1 · 1 location(s) · Joanne Kurtzberg, MD · NCT02254863Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
NA · 11 location(s) · West China Second University Hospital · NCT07371182Histiocytic Disorder Follow-up Study
Phase N/A · 1 location(s) · University of Alabama at Birmingham · NCT05915208Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Prospective Cohort for Adult Hemophagocytosis
Phase N/A · 1 location(s) · Samsung Medical Center · NCT03117010International Rare Histiocytic Disorders Registry (IRHDR)
Phase N/A · 15 location(s) · The Hospital for Sick Children · NCT02285582Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm
Phase 1/Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT07525466Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
Phase 2/Phase 3 · 1 location(s) · Beijing Friendship Hospital · NCT07339345DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Phase N/A · 1 location(s) · University of Alabama at Birmingham · NCT05898477Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT04902807Prospective Validation of the OHI Index
Phase N/A · 2 location(s) · Meir Medical Center · NCT05882175Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07187193Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT04665674Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Phase 2 · 12 location(s) · Carl Allen · NCT04079179Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
Phase 2 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05762640Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT03990428INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
Phase N/A · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT05277272Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943198Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Phase 4 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07270835ECD-Score: a Study on Erdheim-Chester Disease
Phase N/A · 7 location(s) · Meyer Children's Hospital IRCCS · NCT07454343
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.